Navigation Links
AlphaRx Unveils its China Strategy

    AlphaRx plans to open an R&D facility and manufacturing plant in China
    with local partners, to introduce innovative drug products to the fastest
    growing pharmaceutical market in the world.

MARKHAM, ON, July 21 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company, utilizing proprietary drug delivery technology to develop novel formulations of drugs, is forging ahead with its growth strategy for Greater China. As part of this strategy, AlphaRx is poised to open a "state of the art" R D and pilot plant facility in China with local partners. The R D facility will focus on the development of innovative drug products targeting infectious disease and various forms of cancer. Additionally, the Company, together with its local partners, plans to develop adjuvant vaccines to treat influenza, such as H5N1 and H1N1 strains.

AlphaRx currently has a topical NSAID awaiting near-term registration in China and is developing a second product - GAI-122 - an injectable nanoemulsion, in collaboration with Gaia BioPharma for the treatment of acute hepatitis, a therapy with a multi-million dollar potential indication in China.

The Chinese government has been a strong supporter of the life sciences industry. It plans to further increase its investment in the sector through a variety of grants and awards in some of its leading science and technology parks and through the National Program 863, originally established in March 1983 by Deng Xiaoping to award grants to science and technology projects that have significant commercial value. Most notably, in November 2008, China launched the Mega New Drug Development Program, a plan to invest $10 billion over the next 13 years, with the aim of creating a China-based innovative drug development industry.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
2. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
3. AlphaRx Shareholder Update
4. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
5. AlphaRx Signs Cooperative Research and Development Agreement with US Army
6. AlphaRx Provides Corporate and Development Update
7. AlphaRxs Indaflex(TM) Continues its Clinical Development
8. AlphaRx CEO Accumulates More Company Shares
9. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
10. AlphaRx Announces Debt Conversion
11. AlphaRx To Present at 47th Annual ICAAC
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
Breaking Medicine Technology: